Tanzania

Moxifloxacin TB Clinical Trials (Bayer HealthCare)

Bayer HealthCare and the TB Alliance partnered for a global clinical trial program to study the potential of an existing antibiotic, moxifloxacin, to shorten the standard six-month treatment of pulmonary tuberculosis.

Millennium Villages Project

As three out of eight Millennium Development Goals (MDGs) are health-related, the Novartis Foundation for Sustainable Development agreed in 2007 to support the Millennium Villages Project (MVP) in health-related research interventions. The MVP was founded with the goal of helping impoverished communities in rural Africa achieve the MDGs formulated and agreed to by all member countries of the United Nations. The MVP is active at 12 sites in ten African countries. In 2007, the Novartis Foundation started financing one of the six Millennium Villages in Tanzania, the Ilolangulu Village.

Merck Praziquantel Donation Program

In April 2007, Merck signed a partnership agreement with the World Health Organization to supply 200 million tablets of Cesol® 600 (praziquantel) for the treatment and prevention of schistosomiasis over a 10 year period.

Merck Mectizan Donation Program

Onchocerciasis, or river blindness, is a leading cause of infectious blindness in the developing world. The Merck Mectizan Donation Program (MDP) was launched in 1987, when Merck & Co., Inc. announced that it would donate Mectizan (ivermectin), for the treatment of onchocerciasis to all who needed it for as long as needed.

Merck & Co., Inc. HIV/AIDS Programs - Africa

In 2009, with support from The Merck Company Foundation, the Earth Institute at Columbia University launched a community health worker training program to strengthen community health services for over 400,000 people in 10 African countries as part of the Millennium Villages project. The initiative aims to develop a professional cadre of 800 community health workers to fill a critical gap in primary healthcare provision for rural communities throughout Africa.

Medicines for Malaria Venture (MMV)

Seeks to discover, develop and deliver new antimalarial medicines suitable for use in developing countries.

International Trachoma Initiative (ITI)

The International Trachoma Initiative (ITI) is the only organization dedicated solely to the elimination of blinding trachoma.

International Partnership for Microbicides (IPM)

The International Partnership for Microbicides provides the license and technology to develop, manufacture and distribute newly developed microbicide compounds to reduce sexual transmission of HIV in developing countries.

HPV Vaccine & Cervical Cancer

Cervical cancer is the second most common cancer in women worldwide, with about 500,000 new cases and 250,000 deaths occurring each year. Almost 80% of cases occur in low-income countries, where cervical cancer is the number one cause of cancer in women. Virtually all cervical cancer cases (99%) are linked to genital infection with human papillomavirus (HPV), a family of virus types which also causes genital warts and other forms of cancer.

Global Pharma Health Fund

The Global Pharma Health Fund e.V. (GPHF) is a charitable organization initiated and funded exclusively by donations from Merck KGaA, Darmstadt Germany. In 2007, it took over the work of the former German Pharma Health Fund, which was set up in 1985. The organization aims to improve health care in the context of development assistance, in particular the use of the GPHF-Minilab in the fight against counterfeit drugs.

Pages